Their findings suggested that initial biomarker assessment using cfDNA, plasma first instead of tissue, with tissue reserved for PD-L1 immunohistochemistry and reflex testing when cfDNA is negative for known oncogenic driver mutations, improves the biomarker discovery rate, TAT, and increases the number of newly diagnosed metastatic NSCLC patients receiving guideline-complete biomarker testing. The gene discussed is CD274; the disease is non-small cell lung carcinoma.